I like to correct your cash on hand amount there. It is roughly...

I like to correct your cash on hand amount there. It is roughly $20mil cash on hand inclusive of the $10.8mil upfront payment from ADVANZ PHARMA next week and around $1mil option conversion yesterday. That leaves us an EV of unbelievably dirt cheap $50mil for a phase 3 clinical drug with 1st distribution deal $220mil milestone payments + 15%-20% royalties on net sales for EU+Canada+Aus market. Plus upcoming distribution deal of potential double prize compared to the 1st deal, for the US market. Then China market deal, then Japan+Korea+Rest of Asia deal.

The traders have been trading to squeeze out cheap shares from clueless holders but this stock has so much strong fundamental upside potential for me to ignore.

Just on milestone payments potential, based on the EU deal with ADVANZ PHAMA, for all major markets, DXB is looking at potential of up to $1.2bil milestone payments. Then add in 15%-20% ANNUAL royalties of 15%-20% on global sales, we are looking at potential of $150mil-$300mil income for DXB each and every year here.

It would still be very attractive figures for milestone payments and ANNUAL royalties income for DXB (with MC of tiny $70mil on an EV of $50mil) no matter how you look at it, what angle you want to look at it or how much you want to cut and trim those figures down.

This is a very compelling risk-reward proposition to me.

Commercial manufacturing arrangements are well advanced!

ADVANZ PHARMA wouldn't blindly throw $11mil (upfront payment) away if they dont like the phase 3 results so far. I believe they must have been presented the partial interim results under an NDA (Non-Disclosure Agreement).